2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 23

Covalent High Molecular Weight HMGB1 Complexes in Muscle Regeneration: Implications in Inflammatory Myopathy

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 444

Criterion Validity of the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) Questionnaire and FLARE-RA Cut-offs for Clinical Decision Making: International Collaboration

Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 800

Cryopyrin-Associated Periodic Syndrome in Korea: 19 Years of Experience

Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

9:00AM-11:00AM: Abstract Number: 775

Cutaneous Gene Expression Signatures in Juvenile Myositis Reveal a Prominent IFN Signature in Lesional Skin

Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

9:00AM-11:00AM: Abstract Number: 534

CXCL13 Serum Levels and Circulating Follicular Helper T-Cells Decrease After Co-stimulation Blockade with Abatacept in Rheumatoid Arthritis

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 15

CYR61/TGF-β Axis Promotes Adventitial Fibrosis of Takayasu Arteritis in the IL-17 Mediated Inflammatory Microenvironment

Cytokines & Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 543

Cytokine Signaling Pathways Inhibited by Different Biologics in Rheumatoid Arthritis Patients

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 560

Dactylitis Occurrence in Early Spondyloarthritis: Five Years Data from a French National Prospective Cohort

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 769

Damage in Takayasu‘s Arteritis Is Associated with Age at Symptom-onset, Disease-duration and Corticosteroid Dose but Not Relapse in Routine Follow-up

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 644

Decreased HVEM Expression in Lupus Patients and Impact of HVEM Knockout Mouse Model of Lupus Suggest a Role for BTLA Signaling in Disease Pathogenesis

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 476

Decreased Muscle Mass, a Novel Predicting Indicator for One-year Radiographic Progression in Rheumatoid Arthritis: A Real-world Cohort Study

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 116

Defective EZH2 Expression Attenuates Treg Differentiation in Rheumatoid Arthritis

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 299

Definition of New Ultrasound Enthesophytes Score: Application in a Consecutive Series of IBD Patients

Imaging Of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 717

Dental Health in Systemic Sclerosis Patients Risk Factors and Comorbidities

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 178

Depression: A Common Comorbidity in Rheumatic Diseases. a Case-Control Study

Epidemiology & Public Health Poster I: RA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].